Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Inclusion Criteria:

-Patients must meet all of the following inclusion criteria:

Pathologic confirmation of stage III or IV NSCLC.
Docetaxel therapy for cancer is clinically indicated.
KPS>=60% *ANC<1,000/mcl and Platelets<100/mcl

Exclusion Criteria:

-Patients must meet none of the following exclusion criteria:

WBC< 4,000/µl, hemoglobin < 10 g/dl, platelet count < 100,000/µl, total bilirubin > ULN, AST >1.5 x ULN, alkaline phosphatase > 2.5 x ULN, creatinine > 1.5 mg/dl or creatinine clearance < 50 ml/min/1.7 m2), (ANC > 10,000/µl)
Prior docetaxel
Patient must have recovered from all previous treatment-related toxicity
Concurrent use of any botanicals for anticancer intent
Use of Jin Fu Kang or any of its constituent botanicals in the previous three weeks.
History of allergy to any of the constituent botanicals in Jin Fu Kang.
Pregnant or lactating women or women of childbearing potential not using effective contraception. A negative pregnancy test must be documented during the screening period for women of childbearing potential.
Concurrent active cancer.
Concurrent use of immunosuppressives: as an immunostimulant, astragalus-containing products are contraindicated for patients on immunosuppressive therapy.